Navigation Links
Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:10/22/2007

n patients with advanced solid tumors and in patients co-infected with HCV and HIV.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the protocol will not be approved, the risk that the company will experience delays or difficulties in enrolling patients in the study, and the risk that the results from this trial will not be consistent with the results of prior trials or pre-clinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and quarterly report on Form 10-Q for the quarter ended July 31, 2007. The company cautions investors not to place undue re
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... At the American Association of Neurological Surgeons ... D.C. , Elekta will highlight Leksell Gamma ... leverage the enormous amount of data – generated by ... – to advance clinical research and further optimize patient ... solution that allows practitioners to store, retrieve, and analyze ...
(Date:5/1/2015)... 2015 Pharmacyclics, Inc. (the "Company") (NASDAQ: ... ended March 31, 2015, as well as general business ... conference call will be held. Key Highlights ... 31, 2015 increased to $206 million from $119 million ... Worldwide IMBRUVICA ® (ibrutinib) net product revenue of ...
(Date:5/1/2015)... -- Cambrex Corporation (NYSE: CBM ) reports results for ... Highlights , Sales increased 18% compared to the ... impact, driven by Innovator products and Controlled Substances. , ... first quarter of 2014. , GAAP Diluted EPS from ... last year and Adjusted Diluted EPS was $0.29 compared to ...
Breaking Medicine Technology:Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 2Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 27Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 28Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 29Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 30Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 31Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 32Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 33Cambrex Reports First Quarter 2015 Financial Results 2
... today announced that the United States Food and ... Drug application (IND) to commence clinical trials advancing ... acute breakthrough seizures.   Following initial pre-IND discussions with ... based upon the encouraging human pharmacokinetic results seen ...
... 2012  Genomic Health, Inc. (Nasdaq: GHDX ) today ... goal of improving the quality of diagnosis, communication and support ... and rare genetic conditions.   The subsidiary is expected to be ... service in 2013.  The new venture will be led by ...
Cached Medicine Technology:Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel Intranasal Diazepam Formulation 2Genomic Health Announces Formation of New Genetics Subsidiary 2Genomic Health Announces Formation of New Genetics Subsidiary 3Genomic Health Announces Formation of New Genetics Subsidiary 4
(Date:5/3/2015)... " Bubbly Walrus ” was featured on NewsWatch as part ... latest and coolest applications on the market for iOS, Android, ... expert, conducted the app review and shared with viewers how ... games to play on smartphones are the ones that get ... with a video game that just absorbs attention, why not ...
(Date:5/3/2015)... Mateo, CA (PRWEB) May 03, 2015 ... service, MnemeTherapy® at two upcoming area seminars. The first ... the PSA Annual Regional Stroke Conference to be held ... be offered on Wednesday, May 13 during the Dementia ... Plaza. , “These seminars offer an excellent opportunity ...
(Date:5/2/2015)... As one of only 30 Illinois ... and Health Achievement and Recognition Program (SHARP) certification, ... by the Illinois Department of Labor to host this ... SHARP certification by the Occupational Safety and Health Administration’s ... continued to meet or exceed all of the necessary ...
(Date:5/2/2015)... 02, 2015 ProText Kinetic 2 is a ... Final Cut Pro X. ProText Kinetic 2 features 40 ... Final Cut Pro X . Easily create interactive text ... Film Studios' ProText Kinetic 2. , Using ProText Kinetic is ... two ProText Kinetic presets in the FCPX timeline. Playback ...
(Date:5/2/2015)... Ohio (PRWEB) May 02, 2015 On ... Liverpool City Hospital (ELCH) gathered to celebrate improvements in ... River Valley Health Partners (RVHP), had zero acquired ventilator ... urinary catheter associated infections. ELCH was also recently named ... The management team at ELCH credited the teamwork of ...
Breaking Medicine News(10 mins):Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... Findability with Flexibility of Vivisimo,s Velocity Search Platform , ... a powerful new level of social and personalized search for ... is helping the leading UK medical website expand its offerings ... , (LOGO: http://www.newscom.com/cgi-bin/prnh/20080626/NEW046LOGO ) , ...
... MOINES, Iowa, Nov. 24 Vitech Systems Group, Inc. ... Administration System Implementation at the Iowa Public Employees, Retirement ... funds in the U.S., contracted with Vitech in 2006 ... The solution provides advanced capabilities and increases efficiency, transforming ...
... Calif. Nov. 24, 2008Researchers at the University of Southern ... for aggressive prostate cancer blocks the development of prostate ... study in the Proceedings of the National Academy ... cancer therapy for humans. , "This research has ...
... has directed KH Real Estate to issue a boil water advisory ... Township, Armstrong County, after samples taken by DEP tested positive for ... DEP received complaints from residents after two customers were hospitalized with ... testing for the bacteria. , ...
... system for advanced radiation therapy, today announced that Rafael (Ralph) Vaello ... December 1, 2008. Mr. Vaello, who will report to TomoTherapy CEO ... sales and field marketing group for Philips Healthcare’s Oncology Imaging division. ... ...
... million of them currently abstain from alcohol, drugs , , ... million Americans over the age of 12 participate in ... including 2.3 million who currently abstain from use of ... released Monday by the federal Substance Abuse and Mental ...
Cached Medicine News:Health News:Vivisimo Helps OnMedica Deliver Personalized Search and Extend Social Search to Public-Facing Health Portal 2Health News:Vivisimo Helps OnMedica Deliver Personalized Search and Extend Social Search to Public-Facing Health Portal 3Health News:Vitech's V3 Pension Administration Software Improves IPERS' Business 2Health News:USC researchers identify novel approach for suppressing prostate cancer development 2Health News:Pennsylvania DEP Directs Shadyside Water Supply to Issue Boil Water Advisory 2Health News: TomoTherapy Names Rafael Vaello Vice President of Global Sales : Former Philips Healthcare executive brings proven sales experience in oncology, imaging industries 2Health News:5 Million People a Year Use Self-Help Addiction Programs 2
... CIC are formed as a host ... cleared by phagocytosis. If not cleared, CIC ... inflammatory response. CIC are increased in Systemic ... may be involved in other autoimmune disorders ...
Microalbumin Linearity Control...
The K-ASSAY Lipid Controls are assayed controls produced from fresh human sera to monitor the accuracy and precision of quantitative lipid determinations of human sera specimens....
... ASO / RF / CRP ... be used as a consistent ... for monitoring the performance of ... Factor (RF), and C-Reactive Protein ...
Medicine Products: